Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist

Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibite...

Full description

Saved in:
Bibliographic Details
Published in:Journal of asian natural products research 2023-05, Vol.25 (5), p.484-496
Main Authors: Wu, Hui, Wang, Gao-Rui, Wang, Xin-Ting, Bai, Yu-Yan, Yuan, Jin-Feng, Yang, Liu, Huang, Fei, Shi, Hai-Lian, Wu, Xiao-Jun
Format: Article
Language:English
Subjects:
3T3-L1 Cells
Animals
Astragaloside IV
Cell differentiation
db/db mice
Gene expression
Hyperlipidemia
Hypertension
Insulin
Insulin resistance
Lipid metabolism
Lipids
Lipogenesis
metabolic disorder
Metabolic disorders
Mice
Mice, Inbred C57BL
Mice, Obese
Obesity
Obesity - drug therapy
Obesity - metabolism
Palmitic acid
Peroxisome proliferator-activated receptors
PPAR gamma - genetics
PPAR gamma - metabolism
PPARγ
RNA, Messenger
Rosiglitazone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity.
ISSN:1028-6020
1477-2213
DOI:10.1080/10286020.2022.2098726